First-Line Chemo-Immunotherapy for Extensive-Stage Small-Cell Lung Cancer: A United States-Based Cost-Effectiveness Analysis

OBJECTIVE: This study aimed to assess the cost-effectiveness of two recently approved first-line chemo-immunotherapies [atezolizumab combined with etoposide and platinum (AEP) and durvalumab combined with etoposide and platinum (DEP)] for patients with extensive-stage small-cell lung cancer (ES-SCLC...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Qiao, Luo, Xia, Yi, Lidan, Zeng, Xiaohui, Tan, Chongqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276096/
https://www.ncbi.nlm.nih.gov/pubmed/34268124
http://dx.doi.org/10.3389/fonc.2021.699781

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276096/
https://www.ncbi.nlm.nih.gov/pubmed/34268124
http://dx.doi.org/10.3389/fonc.2021.699781

Ejemplares similares